checkpoint inhibitors
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 20, 2023
Combined Dostarlimab, Standard of Care Improves Survival for Endometrial Cancer Patients
Adding the programmed cell death protein-1 (PD-1) checkpoint inhibitor dostarlimab (Jemperli, GSK) to carboplatin ...
MAY 3, 2023
Outcomes Less Than Expected in Largest Real-World Study of ICIs
Real-world response to immune checkpoint inhibitors (ICIs) may be poorer than outcomes reported in pivotal clinical ...
NOVEMBER 19, 2020
Immunotherapy Toxicities
Immune checkpoint inhibitors and adoptive cell transfer therapies have unlocked new avenues to treat cancer, but ...
OCTOBER 12, 2020
Checkpoint Inhibitors Appear to Threaten Liver Grafts
Liver transplant patients who receive checkpoint inhibitors for the treatment of cancer may be at increased risk ...
AUGUST 14, 2020
Early AE Recognition Helps Preserve ImmunoRx Benefits
Denver—For the minority of patients who develop significant immune-related adverse events while taking ...
JULY 11, 2018
Checkpoint Inhibitors Advancing in Multiple GI Cancers
Immunotherapy with checkpoint inhibitors, specifically agents targeting programmed death-1 (PD-1), are advancing in ...
MAY 31, 2017
AACR: Dr. Padmanee Sharma Discusses Boosting Checkpoint Inhibitors
Dr. Sharma, an oncologist at The University of Texas M.D Anderson Cancer Center, in Houston, discusses her recent ...
MAY 16, 2017
CAR Therapy Research Heats Up
Boston—While checkpoint inhibitors may be stealing the cancer news spotlight these days, advances in chimeric ...
APRIL 18, 2017
2nd-Line Pembro in NSCLC: Survival Curve’s Long Tail
Vienna—As checkpoint inhibitor therapy is introduced into additional solid tumor types, investigators and ...
APRIL 13, 2017
Immunotherapy Associated With Higher Response Rates in mTNBC Patients
For patients with mTNBC, the median survival with a checkpoint inhibitor was about twice as long as would be ...
APRIL 10, 2017
Immunotherapies Being Tested Earlier in NSCLC
Copenhagen, Denmark—In the front-line treatment of non-small cell lung cancer (NSCLC), the checkpoint ...
DECEMBER 14, 2016
